NfL

Neurofilament light chain and glial fibrillary acidic protein as biomarkers of peripheral nervous system involvement in multiple sclerosis: diagnostic and prognostic evaluation

Biomarkers in Multiple Sclerosis The identification of biomarkers in multiple sclerosis (MS) has gained traction as a pivotal aspect of […]

Neurofilament light chain and glial fibrillary acidic protein as biomarkers of peripheral nervous system involvement in multiple sclerosis: diagnostic and prognostic evaluation Read Post »

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis

Study Overview The research investigates the effects of ozanimod, an oral medication, on key biomarkers associated with neurodegeneration and inflammation

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis Read Post »

Comparative Analysis of Mouse CSF Proteins in Experimental Autoimmune Encephalomyelitis Model and Cuprizone-Induced Demyelination Model by Olink Proteomics

Study Overview This research investigates protein alterations in the cerebrospinal fluid (CSF) using two distinct models of demyelination: Experimental Autoimmune

Comparative Analysis of Mouse CSF Proteins in Experimental Autoimmune Encephalomyelitis Model and Cuprizone-Induced Demyelination Model by Olink Proteomics Read Post »

Scroll to Top